DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-31

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:

Does DNA methylation changes distinguish Brugada patients from healthy controls?

Does DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Southeast Asian Brugada Syndrome Cohort

NCT04232787

Brugada Syndrome

UNKNOWN

Genetic Markers of Cardiovascular Disease in Epilepsy

NCT02824822

Epilepsy Seizures Syncope +2 more

RECRUITING

Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders

NCT04257994

Arrhythmogenic Right Ventricular Dysplasia Brugada Syndrome Cardiac Channelopathy

ACTIVE_NOT_RECRUITING

Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

NCT07257289

Hereditary Heart Diseases

NOT_YET_RECRUITING

Genetic Autopsy and Sudden Death

NCT02920203

Sudden Death

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Investigators will enroll 10 patients with Brugada syndrome and 10 age and sex matched healthy controls. We will collect 5 mL of peripheral blood and will analyze genome-wide DNA methylation via EPIC array platform. Bioinformatic algorithms and network analysis will be applied to identify possible diagnostic and predictive biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brugada Syndrome Sudden Cardiac Death Due to Cardiac Arrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subjects

The control group consisted of unrelated age- and sex-matched healthy subjects as volunteer blood donors with no evidence of any ECG abnormalities, inherited arrhythmia, genetic cardiomyopathy, and no history of ventricular arrhythmia, unexplained syncope, unexplained sudden cardiac arrest/ death.

No interventions assigned to this group

Brugada patients

Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.
* \>18 years
* Unrelated patients